Delving into the Latest Updates on 20-valent Pneumococcal Conjugate Vaccine(Pfizer) with Synapse

Overview

Basic Info

Drug Type

Inactivated vaccine, Prophylactic vaccine, Multivalent vaccine

+ [1]

Synonyms

Multivalent Pneumococcal conjugate vaccine, Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal conjugate vaccine

+ [13]

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesOtorhinolaryngologic DiseasesRespiratory Diseases

Active Indication

invasive Streptococcus pneumoniae infectionOtitis MediaPneumococcal Infections+ [5]

Inactive Indication

COVID-19Influenza, Human

Originator Organization

Wyeth Pharmaceuticals LLC

Active Organization

Pfizer Inc.Pfizer Europe MA EEIGPfizer Pharmaceuticals Korea Ltd.

+ [4]

Inactive Organization-

License Organization

Chong Kun Dang Pharmaceutical Corp.Pfizer Pharmaceuticals Korea Ltd.

Korea Vaccine Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

United States (08 Jun 2021),

Invasive streptococcal disease

RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States)

Login to view timeline

Structure/Sequence

Sequence Code 1148399

The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea.
This study is seeking for participants who are:
* Infant, children and adolescents aged 6 weeks to under 18 years or adult who are 18 years or older
* Prescribed Prevenar 20 by their physician as per approved product label
All participants in this study will receive Prevenar 20 vaccine.
1 dose (0.5 mL) of Prevenar 20 will be given into a muscle, preferably to the shoulder muscle.
We will look at the experiences of people receiving the study medicine. This will help us see if the study medicine is safe.
Participants will take part in this study for 28 days. During this time, study doctor collects the data of subjects to understand the safety of study medicine. There is no strict fixed visit schedule. If subjects are unable to visit the study clinic 28 days after Prevenar 20 vaccine was given then the safety information will be collected by telephone or e-mail.

Start Date01 Sep 2025

Sponsor / Collaborator

Pfizer Inc.

NCT07019909

/ Not yet recruitingPhase 1

A Phase 1, Randomized, Double-Blind, Third-Party-Unblinded Trial to Evaluate the Safety and Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine (20vPnC) and 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Pneumococcal Vaccine-Naïve Adults 50 Years of Age and Older in China

This Phase 1, randomized, double-blind, third-party-unblinded study will be conducted at investigational sites in China. The purpose of the study is to learn about the safety and immune response of 20vPnC and 13vPnC in Chinese adults 50 years of age and older who did not receive any of pneumococcal vaccine in the past

Start Date14 Jul 2025

Sponsor / Collaborator

Pfizer Inc.

NCT07023081

/ Not yet recruitingPhase 1

A Phase 1, Single-Arm Study to Evaluate the Safety and Tolerability of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Adults, Children, and Infants

The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC). This vaccine will be given as per the age-specific dosing schedules among healthy adults, children and infants in China.
This study is seeking healthy participants of 5 specific age groups:
* Group 1: Adults ≥18 to <50 years of age
* Group 2: Children ≥2 to <6 years of age
* Group 3: Children ≥12 months to <2 years of age
* Group 4: Infants ≥7 to <12 months of age
* Group 5: Infants ≥42 to ≤98 days of age
All participants in this study will receive 20vPnC as per the age-specific dosing schedules:
* Group 1: participants will receive 1 dose of 20vPnC.
* Group 2: participants will receive 1 dose of 20vPnC.
* Group 3: participants will receive 2 doses of 20vPnC. Dose 2 will be given 56 to 70 days after Dose 1.
* Group 4: participants will receive 3 doses of 20vPnC. Dose 2 will be given 28 to 56 days after Dose 1, and Dose 3 will be given at 365 to <455 days of age and at least 56 days after Dose 2.
* Group 5: participants will receive 4 doses of 20vPnC. Dose 2 will be given 42 to 63 days after Dose 1, and Dose 3 should be given 42 to 63 days after Dose 2, and Dose 4 should be given at 365 to <455 days of age.
The study will look at the experiences of people receiving the study vaccine. This will help decide if the study vaccine is safe.
The total duration of taking part in the study from each group is:
* Participants in Group 1 and Group 2 will take part for about 6 months, with 6 visits.
* Participants in Group 3 will take part for about 8 months, with 9 visits.
* Participants in Group 4 will take part for about 12 months, with 8 visits.
* Participants in Group 5 will take part for about 16 to 19 months, with 11 visits.

Start Date16 Jun 2025

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

100 Translational Medicine associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

100 Patents (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

2,228

Literatures (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

31 Dec 2025·Human Vaccines & Immunotherapeutics

PCV20 for the prevention of invasive pneumococcal disease in the Mexican pediatric population: A cost-effectiveness analysis

Article

Author: Vinand, Elizabeth ; Torres, Gustavo Ivan ; Huang, Liping ; Ta, An ; Wannaadisai, Warisa ; Huerta, José Luis

The introduction of a pneumococcal conjugate vaccine (PCV) covering 13 serotypes (PCV13) into the Mexican pediatric national immunization program (NIP) has substantially reduced the burden of pneumococcal disease (PD) since 2010. This study aimed to estimate the impact of replacing either PCV13 or 15valent PCV (PCV15) with 20-valent PCV (PCV20) in the Mexican pediatric NIP. A decision-analytic Markov model was developed to compare the cost-effectiveness of PCV20 versus lower-valent vaccines from a Mexican public health sector (payer) perspective over 10 years. Epidemiological and cost inputs were sourced from Mexican data. Direct and indirect vaccine effects were estimated using PCV13 clinical effectiveness, 7-valent PCV efficacy studies, and PCV13 impact data in Mexico. The estimated disease and cost impact of PCV20 was compared with PCV13 and PCV15, all under a 2 + 1 dosing schedule. A discount rate of 5% per annum was applied to costs and health outcomes. Model robustness was evaluated through sensitivity analyses, including deterministic sensitivity analysis (DSA), probabilistic sensitivity analysis (PSA), and additional scenario assessments. PCV20 was estimated to provide considerably more health benefits than both comparators by averting more cases of PD compared with both PCV13 and PCV15, as well as a total cost saving of over 10 billion Mexican pesos. The DSA, PSA, and scenario assessments confirmed minimal deviation from the base case. Therefore, the introduction of PCV20 (2 + 1) into the Mexican pediatric NIP is expected to reduce the burden of PD and medical costs compared with lower-valent alternatives.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Pneumococcal vaccine hyporesponsiveness in people living with HIV: A narrative review of immunological mechanisms and insights from minimally invasive lymph node sampling

Review

Author: de Vos, Danny W. ; Visser, Leo G. ; Jochems, Simon P. ; Loe-Sack-Sioe, Giovanni E. ; Roukens, Anna H. E.

Despite highly effective antiretroviral therapy, people living with HIV (PLWH) remain at elevated risk for invasive pneumococcal disease. Clinical studies show that, even with high CD4⁺ counts, PLWH exhibit diminished serological responses and rapid antibody decline following pneumococcal vaccination, plausibly due to underlying immune dysfunction. Germinal centers (GCs), located within lymph nodes, are essential for generating high-affinity antibodies, but are structurally and functionally disrupted in PLWH. These local impairments, combined with systemic immune dysregulation, contribute to vaccine hyporesponsiveness in PLWH. This narrative review links immunological findings from experimental and in vivo studies to clinical pneumococcal vaccine trials, to investigate mechanisms that may be leveraged to strengthen vaccine-induced immunity in PLWH. We also highlight the application of fine needle aspiration (FNA) of the lymph node as a way to study pneumococcal vaccine hyporesponsiveness in the GC and provide potential direction to improve responses for next-generation pneumococcal conjugate vaccines in PLWH.

31 Dec 2025·Expert Review of Vaccines

Cost-effectiveness analysis of 20-valent pneumococcal conjugate vaccine (PCV20) to prevent pneumococcal disease in the Greek pediatric population

Article

Author: Psarra, Marina ; Perdrizet, Johnna ; Gourzoulidis, George ; Kokkinaki, Ioanna ; Tzanetakos, Charalampos ; Barmpouni, Myrto ; Kossyvaki, Vasiliki

OBJECTIVE:

The aim of the present study was to evaluate the cost-effectiveness of 20-valent pneumococcal conjugate vaccine (PCV20) compared to 13-valent pneumococcal conjugate vaccine (PCV13) and 15-valent pneumococcal conjugate vaccine (PCV15) for prevention of pneumococcal disease in the pediatric population in Greece.

METHODS:

A published decision-analytic Markov model was adapted from payer perspective, to compare PCV20 (under a 3 + 1 dosing schedule per EMA approval) with PCV13 and PCV15 (both under a 2 + 1 dosing schedule) over a 10-year time horizon. Inputs for epidemiology, serotype coverage, vaccine effectiveness, utilities, and direct medical costs (€2024) were sourced from published literature and official data. Model outcomes included number of invasive pneumococcal disease (IPD), noninvasive hospitalized pneumonia, non-hospitalized pneumonia and otitis media (OM) cases, attributable deaths, costs, quality-adjusted life-years (QALYs) for each vaccination strategy and the incremental cost-effectiveness ratios for each comparison. Scenario analyses assessed PCV20 in a 2 + 1 schedule per recent national recommendations.

RESULTS:

The analysis indicated that, vaccination with PCV20 compared to PCV13 and PCV15 prevents an additional 1,953 and 1,514 cases of IPD 54,956 and 42,069 noninvasive hospitalized and non-hospitalized pneumonia cases, 343,353 and 271,864 OM cases and 1,377 and 987 deaths respectively, resulting in incremental gain of 23,065 (vs PCV13) and 17,118 (vs PCV15) QALYs respectively. The lower number of pneumococcal disease cases with PCV20 compared to PCV13 and PCV15, translated to a reduction in total medical care cost of €249 M vs PCV13 and €192 M vs PCV15 over the modeled time horizon. Scenario analyses showed that PCV20 remained dominant under a 2 + 1 dosing schedule.

CONCLUSION:

Vaccination with PCV20, whether in a 2 + 1 or a 3 + 1 schedule, was estimated to be a dominant vaccination strategy over PCV15 or PCV13 for the prevention of pneumococcal disease in Greek infants, as expansion of serotype coverage prevents additional morbidity and costs.

110

News (Medical) associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

21 May 2025

·www.fiercepharma.com

SK defeats Pfizer in Korean patent feud, opening new lines of business for pneumococcal vaccine

While SK still has to wait until 2027 to manufacture and sell SKYPneumo in Korea, the company plans to “initiate new business in pneumococcal conjugate vaccines” by exporting individual components of its shot to countries with high demand. Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.The win frees up the company to export its shot—which protects against 13 types of pneumococcal bacteria—to various other countries as SK holds out for a domestic launch in 2027. The Supreme Court of Korea has sided with SK on the matter, ruling that the Korean company did not violate a composition patent on Pfizer’s pneumococcal shot Prevnar 13 by shipping components and finished research doses of its own 13-valent immunization, PCV13, to Russia.Korean regulators approved SK’s 13-valent pneumococcal conjugate vaccine under the name SKYPneumo back in 2016, SK explained in a Wednesday press release. Still, the outcome of a previous patent feud with Pfizer has blocked SK from producing and selling its shot in Korea until 2027, when the relevant Pfizer patents are slated to expire.Pfizer filed its latest lawsuit in 2020 after SK exported PCV13 components and finished doses for research to a Russian drugmaker in 2018 and 2019, alleging that this violated the prior settlement, Korea Biomedical Review reports."This latest court decision is meaningful in that it ensures a competitively developed vaccine in Korea does not go to waste but instead finds new opportunity,” Jaeyong Ahn, SK’s CEO, said in a statement. “We will leverage this momentum to improve access to premium vaccines, contribute to a stable global vaccine supply, and achieve sustainable growth." While SK still has to wait until 2027 to manufacture and sell SKYPneumo in Korea, the company said on Wednesday that it plans to “initiate new business in pneumococcal conjugate vaccines” by exporting individual components of its shot to countries with high demand, like those in Southeast Asia and Latin America.SK added that it’s exploring technology transfers through local partnerships, as well.Beyond SKPYneumo, the Korean vaccine specialist is currently developing a 21-valent pneumococcal conjugate shot with partner Sanofi that entered phase 3 testing late last year. SK and Sanofi are also tinkering with a next-generation pneumococcal vaccine that’s expected to offer broader protection than currently approved immunizations. Meanwhile, SK hasn’t only been going up against Pfizer in Korean patent litigation.Late last month, the company notched a win in a patent invalidation suit against Moderna, successfully knocking down the company’s Korean patent tied to mRNA vaccine technology.

VaccinePhase 3Drug ApprovalPatent InfringementmRNA

21 May 2025

·www.prnewswire.com

SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine

No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 to Russia Company plans to export PCV13 vaccine components "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently under development." SEONGNAM, South Korea, May 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, today announced that it the Supreme Court of Korea has ruled in its favor in a patent infringement lawsuit filed by large global pharmaceutical giant Pfizer over its 13-valent pneumococcal conjugate vaccine (PCV13). In 2020, Pfizer claimed that SK bioscience's export of PCV13 individual conjugate bulk substances and research-use finished products to Russia infringed on the composition patent of its vaccine, Prevnar 13. Continue Reading SK bioscience L HOUSE manufacturing plant However, the Supreme Court ruled that the individual conjugates comprising PCV13 do not fall within the scope of Pfizer's patent claims, thereby upholding the lower court's ruling in favor of SK bioscience. The Court also confirmed that the production and supply of PCV13 finished products for research purposes did not constitute patent infringement. SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been prohibited from manufacturing and selling the vaccine in Korea until 2027, when the related patents set to expire. Following the ruling, SK bioscience now plans to initiate new business in pneumococcal conjugate vaccines by exporting individual components of PCV13 to countries with high vaccine demand, such as those in Southeast Asia and Latin America. Technology transfers through local partnerships are also being pursued in parallel. Looking ahead, SK bioscience aims to expand its presence in the global pneumococcal vaccine market. From 2027, the company will be able to manufacture and sell SKYPneumo domestically. In addition, the company is developing a 21-valent pneumococcal conjugate vaccine with global pharmaceutical company Sanofi, which entered Phase 3 global clinical in late 2024. Simultaneously, the two companies are also working on a next-generation pneumococcal vaccine that is expected to offer broader protection than current options. The global pneumococcal vaccine market continues to grow. According to Global Market Insights, the market is projected to grow at a compound annual rate of approximately 5.6% to reach USD 15.1 billion (approximately KRW 21.55 trillion) by 2034. This growth is driven by expanded vaccination programs and support from governments and international organizations like WHO and Gavi. SK bioscience's strong track record in public vaccine supply and cooperation with global health organizations positions it well for future expansion. Jaeyong Ahn, CEO of SK bioscience, said, "This latest court decision is meaningful in that it ensures a competitively developed vaccine in Korea does not go to waste but instead finds new opportunity. We will leverage this momentum to improve access to premium vaccines, contribute to a stable global vaccine supply, and achieve sustainable growth." Meanwhile, SK bioscience recently secured a definitive legal victory in a patent invalidation suit against Moderna, successfully challenging the biotech giant's Korean patent related to messenger RNA (mRNA) vaccine technology. The contested patent covers 'modified nucleosides, nucleotides, and nucleic acids and their uses.' This case, which invalidated the only registered mRNA manufacturing patent in Korea, regarded as a major step in reducing patent-related risks and removing barriers to innovation for domestic companies engaged in mRNA research and development. About SK bioscience SK bioscience is an innovative vaccine and biotech company, committed to vaccine development and manufacturing to enable more equitable access to vaccines around the world. Leveraging strengths on cutting-edge technologies, SK bioscience has been dedicated to promoting human health from prevention to cure across the globe. With the cooperation of domestic and international governments, regulatory agencies, healthcare providers, doctors, and medical experts, all of the SK colleagues are passionately committed to providing high-quality vaccines to those who need them and better public healthcare solutions. - SK bioscience Website - SK bioscience Linkedin Contact SK bioscience Communications Team Changhyun Jin ([email protected]) Jeannie S. Pak ([email protected]) SOURCE SK bioscience WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccinePatent InfringementmRNAPhase 3

19 May 2025

·pmlive.com

Merck receives MHRA approval for adult-specific pneumococcal vaccine Capvaxive

Merck & Co – known as MSD outside the US and Canada – has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its adult-specific pneumococcal vaccine Capvaxive. The vaccine has been authorised to help protect adults aged 18 years and older against illnesses caused by Streptococcus pneumoniae bacteria, including pneumonia and meningitis, which are currently considered a “major public health problem” by the World Health Organization (WHO). There are over 100 different types of pneumococcal bacteria and Merck’s Capvaxive, a single-dose 21-valent-vaccine, is specifically designed to help protect against the ones that are responsible for the majority of adult invasive pneumococcal disease. The MHRA’s decision on Capvaxive occurred through the International Recognition Procedure, a fast-track approval process that takes into account prior authorisations from other regulatory partners, and follows the European Commission’s approval of the vaccine in March. Among the evidence supporting the EU regulator’s decision were results from a phase 3 trial comparing Capvaxive to Pfizer’s 20-valent vaccine (PCV20) in adults who had not previously received a pneumococcal vaccine. Capvaxive was shown to induce non-inferior immune responses compared to PCV20 for all ten serotypes common to both vaccines in adults aged 50 years and older, and generated superior immune responses for ten of its 11 unique serotypes. Merck’s vaccine was also shown to elicit non-inferior immune responses in adults aged 18 to 49 years compared to those aged 50 to 64 years and had a safety profile comparable to PCV20. “As with any medicine, the MHRA will keep the safety and effectiveness of this vaccine under close review,” the UK regulator said. Emma Cerrone, vaccines business unit director, MSD UK, said: “We are delighted with this decision. Pneumococcal infections can lead to serious complications requiring hospital treatment, however immunisation plays a vital role in prevention and can help adults live longer, healthier lives.” Alongside the EU, Capvaxive is approved in the US, Canada and Australia.

Drug ApprovalClinical ResultPhase 3Vaccine

100 Deals associated with 20-valent Pneumococcal Conjugate Vaccine(Pfizer)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	J07AL	-

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
invasive Streptococcus pneumoniae infection	South Korea	Pfizer Pharmaceuticals Korea Ltd.	31 Oct 2024
Otitis Media	United States	Wyeth Pharmaceuticals LLC	27 Apr 2023
Pneumococcal Infections	Canada	Pfizer Canada ULC	09 May 2022
Pneumonia, Pneumococcal	European Union	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	Iceland	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	Liechtenstein	Pfizer Europe MA EEIG	14 Feb 2022
Pneumonia, Pneumococcal	Norway	Pfizer Europe MA EEIG	14 Feb 2022
Invasive streptococcal disease	United States	Wyeth Pharmaceuticals LLC	08 Jun 2021

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute otitis media	NDA/BLA	European Union	Pfizer Europe MA EEIG	26 Jan 2024
Respiratory Syncytial Virus Infections	NDA/BLA	United States	Pfizer Inc.	17 May 2023
COVID-19	Phase 3	United States	Pfizer Inc.	20 May 2021
Influenza, Human	Phase 3	United States	Pfizer Inc.	01 Sep 2020
Infectious Lung Disorder	Phase 2	United States	Pfizer Inc.	05 Jun 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05879107 (CTgov)	Phase 3	Respiratory Syncytial Virus Infections	1,113	PCV20+RSVPreF3 OA investigational vaccine (Co-administration Group)	peefsgntvi(zzhdgtnqvs) = onbsjawvby zfrlyixthm (vppvzcemoa, gknblvmmwi - ojbkdivihq) View more	-	18 May 2025
				PCV20+RSVPreF3 OA investigational vaccine (Control Group)	peefsgntvi(zzhdgtnqvs) = kuwygiwdkv zfrlyixthm (vppvzcemoa, fktltydtta - awhtluxzso) View more
NCT05886777 (CTgov)	Phase 2	COVID-19 \| Infectious Lung Disorder	1,142	QIV+RSVpreF (Group 1: [RSVpreF + BNT162b2] + QIV)	urisfyxgrd = gyrnznbdnz nmvnojjdhb (fvumtdbisb, vnnodnjrwn - qjdcthcqls) View more	-	18 Dec 2024
				Placebo+BNT162b2+RSVpreF (Group 2: [RSVpreF+BNT162b2] + Placebo)	urisfyxgrd = npljmapmnd nmvnojjdhb (fvumtdbisb, yxyfjnjohj - hwnadvdrkv) View more
NCT05875727 (CTgov)	Phase 3	Pneumococcal Infections	405	Pneumococcal vaccine (Cohort 1: 18 to 49 Years)	txvydabdoq = vffjyiixui dsiwlnkpym (rmbpbshdbk, jaalyaizoy - ygtbaxsjlt) View more	-	24 Oct 2024
				Pneumococcal vaccine (Cohort 2: >= 50 Years)	txvydabdoq = xkxvbpffnb dsiwlnkpym (rmbpbshdbk, rjnwtpqlvk - yrafzrqyse) View more
NCT05408429 (CTgov)	Phase 3	Pneumococcal Infections	356	20vPnC (2-Dose 20vPnC)	dvalulaqhh = lipweqmqbi kaczqvjjxq (bmptmqaxlc, psxtnqgpen - lrktecttpy) View more	-	19 Sep 2024
				20vPnC (1-Dose 20vPnC)	dvalulaqhh = tkajdawvwf kaczqvjjxq (bmptmqaxlc, tlcexfmpbw - ofwlhfckwz) View more
NCT04382326 (CTgov)	Phase 3	Pneumococcal Infections	1,997	20-valent Pneumococcal Conjugate Vaccine (20vPnC) (20vPnC)	ouveixlqvu = eriwxhthys fldpsqduza (irylqzdjgk, lusnxnpzng - rhfbnkvtst) View more	-	06 Dec 2023
				13-valent Pneumococcal Conjugate Vaccine (13vPnC) (13vPnC)	ouveixlqvu = nlgrcululf fldpsqduza (irylqzdjgk, lllotxrgrg - cfoepwyjet) View more
NCT04379713 (CTgov)	Phase 3	Pneumococcal Infections	1,511	20vPnC (20vPnC)	xgydvqmqec = pmtlmraycz shwwstdwwk (osdwucuogj, qxferaoxhw - tdbipqothx) View more	-	13 Jun 2023
				13vPnC (13vPnC)	xgydvqmqec = vseexglpsj shwwstdwwk (osdwucuogj, dmwpomvvxr - cbjwzkhkwx) View more
NCT04642079 (CTgov)	Phase 3	Pneumococcal Infections	839	20vPnC+13vPnC (Cohort 1: 20vPnC: >=15 to <24 Months)	shndcnkxpd = heqswowgvu bmrwflihyd (mpetqdxgrb, vnhymgmepw - iiicbkgudh) View more	-	26 Apr 2023
				20vPnC+13vPnC (Cohort 2: 20vPnC: >=2 to <5 Years)	shndcnkxpd = aikjhqqplf bmrwflihyd (mpetqdxgrb, uwgzjpdzgz - weoyoooqtm) View more
NCT04530838 (CTgov)	Phase 3	Pneumococcal Infections	668	20vPnC (20vPnC (SC))	fwulosuhxp = fxofzbifel omutvjlpcq (xujejrpiuu, hwliiazacd - wisplqxkdo) View more	-	21 Apr 2023
				13vPnC (13vPnC (SC))	fwulosuhxp = cfnudllgie omutvjlpcq (xujejrpiuu, aujnukchzl - fgyhoghaaq) View more
NCT04887948 (CTgov)	Phase 3	COVID-19 \| Pneumococcal Infections	570	BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): 20vPnC Vaccination Site)	dazxrnmhwc = pskzcsxbia oyqjfcqkif (wodafwavko, nehtdvzzlm - kmhlnfassc) View more	-	14 Dec 2022
				BNT162b2+20vPnC (Coadministration Group (20vPnC+BNT162b2): BNT162b2 Vaccination Site)	dazxrnmhwc = mwdknxhujr oyqjfcqkif (wodafwavko, pvxhozmxtp - ajjgeyixzh) View more
NCT04546425 (Corporate Publications) Manual	Phase 3	Pneumococcal Infections	-	20-Valent Pneumococcal Conjugate Vaccine	ahamdkackd(ucaqgjzuad) = The safety profile of 20vPnC was favorable and similar to Prevenar 13® (or Prevnar 13® in the U.S.) in this schedule, and concomitant use with common pediatric vaccines was supported and well tolerated xlembhqzkz (gmmnbacyrs )	Non-inferior	19 Sep 2022
				Prevenar 13